Last reviewed · How we verify
NCT07233837: Hylight
Hydrogen Peroxide and Ultraviolet Light for Disinfecting Surfaces in Intensive Care Units
NA trial testing Aerosol of hydrogen peroxide in Infection, Hospital in 5,000 participants. Currently enrolling.
26 February 2027
Quick facts
| Lead sponsor | Hospital Israelita Albert Einstein |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 5,000 |
| Start date | 5 January 2026 |
| Primary completion | 26 February 2027 |
| Estimated completion | 1 March 2027 |
| Sites | 12 locations across Brazil |
Drugs / interventions tested
- Aerosol of hydrogen peroxide
- Irradiation of ultraviolet light
Conditions studied
- Infection, Hospital — all drugs for Infection, Hospital →
- Antimicrobial — all drugs for Antimicrobial →
- Pneumonia Associated With Mechanical Ventilation — all drugs for Pneumonia Associated With Mechanical Ventilation →
- Urinary Tract Infection(UTI) — all drugs for Urinary Tract Infection(UTI) →
Sponsor
Hospital Israelita Albert Einstein
Who can join
18 and older, any sex, with Infection, Hospital or Antimicrobial. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Healthcare-associated infections (HAIs) remain a major problem in intensive care units (ICUs), driven by environmental contamination with multidrug-resistant organisms that persist despite routine manual cleaning. While hydrogen peroxide aerosolization and ultraviolet-C light devices have shown promise in reducing surface contamination, current evidence is inconsistent, mostly derived from single-center studies, and rarely linked to patient-centered outcomes. The investigators will conduct this cluster-randomized, crossover trial in 12 Brazilian ICUs. Each ICU will sequentially implement three strategies: (1) usual surface disinfection; (2) usual surface disinfection followed by hydrogen peroxide aerosolization at 7.9% concentration, applied through a dedicated device inside a protective tent during terminal cleaning of patient beds; and (3) usual surface disinfection followed by automated ultraviolet-C irradiation, also applied under the same tent to shield adjacent occupied beds. The primary outcome will be the antimicrobial utilization, measured as daily defined doses (DDD) of antimicrobials at the ICU level per 100 patient-days, with secondary outcomes including HAI incidence rate, environmental contamination with multidrug-resistant organisms, specific HAIs incidence rate (associated-ventilator pneumonia, central-line associated bloodstream infection, and catheter-associated urinary tract infection), and ICU length of stay costs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07233837
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Infection, Hospital
Currently open trials in the same condition.
- NCT05475574 — Impact of Discontinuing Contact Precautions for Extended-spectrum β-lactamase Enterobacteriaceae in a Geriatric Unit · NA · recruiting
- NCT05153694 — Infectious Complications After Cystectomy: A Prospective Observational Study · recruiting
Other Hospital Israelita Albert Einstein trials
Trials by the same sponsor.
- NCT07447674 — ED Post-Discharge Digital Follow-Up: A Communication Comparison · NA · not yet recruiting
- NCT07398222 — Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study · recruiting
- NCT06726707 — COPPER: A Trial Evaluating Copper-based Products for Incontinence-associated Dermatitis · Phase 2, PHASE3 · withdrawn
- NCT07112846 — Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections · not yet recruiting
- NCT07053228 — e-Natureza Blue Care: Nature-based Virtual Reality and Pain Perception · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07233837 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Israelita Albert Einstein
- Last refreshed: 15 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07233837.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing